The effect of treatment with montelukast on levels of serum interleukin-10, eosinophil cationic protein, blood eosinophil counts, and clinical parameters in children with asthma

Interleukin (IL)-10 is an important immunoregulatory and anti-inflammatory cytokine. IL-10 levels are reduced in asthmatic airways. A regulatory mechanism involving IL-4 induced allergen-specific IL-10 production may be defective in allergic subjects, and this defect potentially contributes to more intense inflammation. The aim of this study was to define the effect of treatment with montelukast on serum levels of IL-10, eosinophil cationic protein (ECP), blood eosinophil counts, and clinical parameters (symptom score and lung function tests) in children with mild and moderate persistent asthma. Twenty-five children with mild-to-moderate persistent asthma and 25 nonatopic healthy children as controls were enrolled in the study. Patients were treated with montelukast for four weeks. Lung function tests for forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF), and forced expiratory flow between 25% and 75% (FEF25-75) were performed before and after treatment. Serum IL-10, ECP levels, and blood eosinophil counts were determined in both the control group and asthmatic children before and after treatment. The mean serum IL-10 levels were significantly lower before treatment than after treatment (1.75±0.9 pg/ml and 5.49±3.6 pg/ml; p<0.001) and in control subjects (5.6±2.8 pg/ml). After four weeks of treatment with montelukast, the mean blood eosinophil count value (608±73/mm3 and 469±57/mm3; p<0.05) but not the ECP value (33.98±24.3 µg/L and 29.03±19.2 µg/L; p>0.05) was significantly decreased. After treatment with montelukast, all clinical parameters and lung function tests improved. We found no statistical correlations between the serum level of IL-10 and the serum level of ECP, eosinophil count, lung function tests, or clinical scores after treatment with montelukast. Montelukast caused a statistically significant increase in serum IL-10 levels and decrease in peripheral blood eosinophil counts over the four-week treatment period. Our study indicates that montelukast provides clinical benefits for children with chronic asthma and produces an anti-inflammatory response by increasing serum IL-10 levels.

Yazar Yüksel B.
Aydemir C.
Üstündag G.
Eldeş N.
Kutsal E.
Can M.
Demirtaş S.
Yayın Türü Article
Tek Biçim Adres https://hdl.handle.net/20.500.12628/7994
Konu Başlıkları Childhood asthma
Eosinophil
Interleukin-10
Montelukast
Koleksiyonlar Araştırma Çıktıları | WoS | Scopus | TR-Dizin | PubMed | SOBİAD
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu
Dergi Adı Turkish Journal of Pediatrics
Dergi Cilt Bilgisi 51
Dergi Sayısı 5
Sayfalar 460 - 465
Yayın Yılı 2009
Eser Adı
[dc.title]
The effect of treatment with montelukast on levels of serum interleukin-10, eosinophil cationic protein, blood eosinophil counts, and clinical parameters in children with asthma
Yazar
[dc.contributor.author]
Yüksel B.
Yazar
[dc.contributor.author]
Aydemir C.
Yazar
[dc.contributor.author]
Üstündag G.
Yazar
[dc.contributor.author]
Eldeş N.
Yazar
[dc.contributor.author]
Kutsal E.
Yazar
[dc.contributor.author]
Can M.
Yazar
[dc.contributor.author]
Demirtaş S.
Yayın Yılı
[dc.date.issued]
2009
Yayın Türü
[dc.type]
article
Özet
[dc.description.abstract]
Interleukin (IL)-10 is an important immunoregulatory and anti-inflammatory cytokine. IL-10 levels are reduced in asthmatic airways. A regulatory mechanism involving IL-4 induced allergen-specific IL-10 production may be defective in allergic subjects, and this defect potentially contributes to more intense inflammation. The aim of this study was to define the effect of treatment with montelukast on serum levels of IL-10, eosinophil cationic protein (ECP), blood eosinophil counts, and clinical parameters (symptom score and lung function tests) in children with mild and moderate persistent asthma. Twenty-five children with mild-to-moderate persistent asthma and 25 nonatopic healthy children as controls were enrolled in the study. Patients were treated with montelukast for four weeks. Lung function tests for forced expiratory volume in 1 second (FEV1), peak expiratory flow (PEF), and forced expiratory flow between 25% and 75% (FEF25-75) were performed before and after treatment. Serum IL-10, ECP levels, and blood eosinophil counts were determined in both the control group and asthmatic children before and after treatment. The mean serum IL-10 levels were significantly lower before treatment than after treatment (1.75±0.9 pg/ml and 5.49±3.6 pg/ml; p<0.001) and in control subjects (5.6±2.8 pg/ml). After four weeks of treatment with montelukast, the mean blood eosinophil count value (608±73/mm3 and 469±57/mm3; p<0.05) but not the ECP value (33.98±24.3 µg/L and 29.03±19.2 µg/L; p>0.05) was significantly decreased. After treatment with montelukast, all clinical parameters and lung function tests improved. We found no statistical correlations between the serum level of IL-10 and the serum level of ECP, eosinophil count, lung function tests, or clinical scores after treatment with montelukast. Montelukast caused a statistically significant increase in serum IL-10 levels and decrease in peripheral blood eosinophil counts over the four-week treatment period. Our study indicates that montelukast provides clinical benefits for children with chronic asthma and produces an anti-inflammatory response by increasing serum IL-10 levels.
Kayıt Giriş Tarihi
[dc.date.accessioned]
2019-12-23
Açık Erişim Tarihi
[dc.date.available]
2019-12-23
Yayın Dili
[dc.language.iso]
eng
Konu Başlıkları
[dc.subject]
Childhood asthma
Konu Başlıkları
[dc.subject]
Eosinophil
Konu Başlıkları
[dc.subject]
Interleukin-10
Konu Başlıkları
[dc.subject]
Montelukast
Haklar
[dc.rights]
info:eu-repo/semantics/closedAccess
ISSN
[dc.identifier.issn]
0041-4301
İlk Sayfa Sayısı
[dc.identifier.startpage]
460
Son Sayfa Sayısı
[dc.identifier.endpage]
465
Dergi Adı
[dc.relation.journal]
Turkish Journal of Pediatrics
Dergi Sayısı
[dc.identifier.issue]
5
Dergi Cilt Bilgisi
[dc.identifier.volume]
51
Tek Biçim Adres
[dc.identifier.uri]
https://hdl.handle.net/20.500.12628/7994
Görüntülenme Sayısı ( Şehir )
Görüntülenme Sayısı ( Ülke )
Görüntülenme Sayısı ( Zaman Dağılımı )
Görüntülenme
263
09.12.2022 tarihinden bu yana
İndirme
1
09.12.2022 tarihinden bu yana
Son Erişim Tarihi
16 Temmuz 2024 20:33
Google Kontrol
Tıklayınız
treatment levels eosinophil montelukast children clinical function expiratory counts before asthma parameters persistent significantly forced asthmatic between anti-inflammatory control subjects 469±57/mm3 (608±73/mm3 pg/ml) Interleukin 98±24 indicates decrease peripheral four-week period significant provides benefits chronic produces
6698 sayılı Kişisel Verilerin Korunması Kanunu kapsamında yükümlülüklerimiz ve çerez politikamız hakkında bilgi sahibi olmak için alttaki bağlantıyı kullanabilirsiniz.

creativecommons
Bu site altında yer alan tüm kaynaklar Creative Commons Alıntı-GayriTicari-Türetilemez 4.0 Uluslararası Lisansı ile lisanslanmıştır.
Platforms